Business Wire

IL-PRICEFX

28.1.2021 15:32:13 CET | Business Wire | Press release

Share
Pricefx Partners with Bain & Company to Launch the Pricing Industry’s First Big Data Powered Benchmarking Platform

Pricefx , the global leader in cloud-native pricing software, today launched PricefxPlasma™, the first big data powered benchmarking platform for the pricing industry. Powered by Bain & Company , PricefxPlasma leverages real world pricing data mapped to industry standard key performance indicators (KPIs). Businesses can discover strategic insights on their own pricing processes and performance as compared to market averages using benchmarks on a pre-defined set of industry relevant KPIs.

“Every company is looking for an edge over the competition and pricing is one of the strongest levers for success in the marketplace,” said Marcin Cichon, CEO and co-founder at Pricefx. “By launching the first pricing analytics and intelligence platform via a joint project with our valued partners at Bain, Pricefx is giving its customers a whole new level of cross-industry insights. PricefxPlasma is a revolutionary new offering for the pricing industry, providing businesses the information and insights to improve pricing efficiency and effectiveness and uncover new opportunities for revenue growth.”

PricefxPlasma combines a massive amount of anonymized and aggregated transaction and quoting data from industries, sliced and segmented by region, industry and other factors. Data is then compiled into more than 20 pricing performance benchmarks, delivered in intuitive visual outputs and designed to answer the most important pricing analytics questions.

KPIs currently measured in PricefxPlasma include:

  • End-to-end price waterfall: detailed price buildup, including on- and off-invoice discounts, cost elements, geographical prices, list prices and margin elements.
  • Deal approval process: deal velocity, the percent of deals outside discount guidelines, the number of steps in the approval process.
  • Price setting: the value capture of price increases, the number of list price changes per year.
  • Measures of customer and product concentration: the percent of customers/products to reach revenue deciles.

Companies often struggle to understand how their pricing practices measure up to industry best practices. Additionally, according to a Bain & Company survey , many B2B companies do not provide their salesforce with the right tools and data to make effective pricing decisions.

“Companies typically assess the effectiveness of their pricing strategy and execution using a combination of anecdotal data, generic or poorly defined benchmarks, and a lot of guesswork,” said Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Having reliable industry benchmarks derived from real world data provides businesses valuable insight to how they measure up to their peers. PricefxPlasma is an attempt to make useful benchmarks readily available and consumable. Having reliable pricing data also can help businesses identify market trends that enable them to make better decisions about strategy, investments and products.”

How PricefxPlasma Works

Pricefx gathers, anonymizes and aggregates its customers’ data into standardized metrics. These metrics are loaded into the PricefxPlasma platform, which aggregates and filters the metrics further to create industry-level benchmarks. The customer's data is anonymized by Pricefx via double-blinding, ensuring that it is impossible to trace individual customer data.

Industry benchmarks are compiled from aggregated metrics from a number of anonymized entities. The resulting benchmarks are distributed to Pricefx’s customers’ environment. Customers can view these benchmarks through a set of standard Pricefx dashboards and customers can also include this data in their own dashboards, allowing for a direct comparison between their company and the benchmark. Benchmarks may be filtered by industry and region to arrive at the desired peer set.

Pricefx partnered with Bain & Company, a global management consulting firm, to develop the benchmarking capabilities and IT systems.

“Combining Pricefx’s world-class pricing software with best practices from Bain’s Pricing and Benchmarking Centers of Excellence, PricefxPlasma provides unique pricing insights never before available that compare your pricing processes and performance to peers,” said Ron Kermisch, Partner at Bain & Company. “Together, we discovered a way to aggregate massive amounts of valuable data and synthesize that data into market relevant KPIs for B2B enterprises to unlock data-driven insights and create a business advantage.”

Pricefx and Bain & Company previously collaborated to launch price Accelerators and the Bain Pricing Navigator powered by Pricefx. Pricefx is a member of the Bain Alliance Ecosystem – a network of best-of-breed partnerships with complementary tool, technology and service providers that accelerates delivery of breakthrough client results.

Availability

PricefxPlasma is available now and is free of charge to Pricefx customers. More information can be found at www.pricefx.com/pricefxplasma . Insights from the platform will also be available to Bain clients and more information can be found at www.bain.com/pricefxplasma .

About Bain & Company

Bain & Company is a global consultancy that helps the world’s most ambitious change makers define the future. Across 59 offices in 37 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise and insight to organizations tackling today’s urgent challenges in education, racial equity, social justice, economic development and the environment. Since our founding in 1973, we have measured our success by the success of our clients, and we proudly maintain the highest level of client advocacy in the industry.

Learn more at www.bain.com and follow us on Twitter @BainAlerts.

About Pricefx

Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Its innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .

PricefxPlasma™ is a trademark of Price f(x) AG.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye